Stem cell transplant plus CAR-T for high-risk leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of your own stem cell transplant and a personalized CAR-T cell therapy called CD19-CAR-T. It is for adults with high-risk acute B-lymphoblastic leukemia whose cancer is in remission after initial chemotherapy, and who are able to receive both treatments safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with high-risk acute B-lymphoblastic leukemia
- Your leukemia is in complete remission after your first chemotherapy
- Doctors were able to make a special CD19-CAR-T treatment from your own cells
- You are healthy enough to receive your own stem cells back after high-dose treatment
- You do not have major organ problems (like heart, liver, or kidney failure)
- You do not have other active cancers, serious infections, or certain viruses (like HIV, hepatitis B, or hepatitis C)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL). The treatment takes your own immune cells, changes them to fight cancer, and then gives them back to you. The goal is to kill leukemia cells and help you go into remission.
This trial combines a special type of stem cell transplant (using half-matched donor cells) with CAR-T therapy and memory T-cell infusions for people with acute leukemia that has not responded to treatment or has come back. The goal is to provide a curative treatment for those who do not have a fully matched donor.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
Hear when a new Acute Lymphoblastic Leukemia ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.